# Revolution Medicines Inc. (RVMD) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $194.23, market value $41.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Revolution Medicines Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 16.0×**. The shares trade at 16.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -3.0%** (5-yr avg -9.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -69.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -48.0%**. Each dollar of assets produces -48.0% of profit.

## Growth
- **EPS growth (1 yr): -66.2%**. Earnings per share fell 66.2%.

## Financial health
- **Interest coverage: -48.8×**. Operating profit covers interest only -48.8×: fragile.
- **Current ratio: 7.14** (quick 7.14). Current assets cover the next year's liabilities 7.14 times.
- **Altman Z-score: 34.76**. A Z-score of 34.76 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Revolution Medicines Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (24 analysts). 24 analysts cover Revolution Medicines Inc.; the consensus is strong_buy, with an average price target of $258.84 (+33% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 219.8%** (YTD 136.2%, 3-mo 3.1%). The shares are up 219.8% over twelve months including dividends.
- **From 52-week high: -13.4%** (236.4% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 46**. An RSI of 46 is neutral.
- **Beta (1 yr): 1.10** (volatility 67%). Beta of 1.10 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RVMD · Page: https://foliofundamentals.com/stocks/rvmd

Not investment advice.